Registration is now open for the launch event of the RETHINKING Alzheimer’s disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00.
The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper ‘RETHINKING Alzheimer’s disease: Detection and diagnosis’. This paper is the first of EBC’s RETHINKING Alzheimer’s disease project, looking at how to improve the detection, diagnosis, care and monitoring of Alzheimer’s disease.
Join the discussion and learn why an accurate and timely diagnosis is so crucial to advancing the science and our understanding of Alzheimer’s. You can look forward to opening remarks from MEP Sirpa Pietikaïnen (EPP, Finland) and a keynote speech highlighting the value of an early diagnosis from a patient perspective.
The keynote will be followed by a panel discussion, moderated by Laura Campo (Eli Lilly and Company), featuring experts involved in the RETHINKING Alzheimer’s disease project, Kristian Steen Frederiksen (co-chair of the EAN Scientific Panel on Dementia & Cognitive Disorders), Maria Teresa Ferretti (Women’s Brain Project) and Linus Jönsson (Karolinska Institutet). The panel will emphasise a clear need for new clinical pathways building bridges between all stakeholders to improve the current situation and prepare for the future.
The event will conclude with a high-level policy panel, moderated by Frédéric Destrebecq (European Brain Council), with MEP Tomislav Sokol (EPP, Croatia), MEP Deirdre Clune (EPP, Ireland), Andrzej Rys (Directorate-General for Health and Food Safety – DG SANTE, European Commission) and Dr. Neerja Chowdhary (World Health Organization).
